Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Prudential Financial Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Prudential Financial Inc trades at $115.48 (market cap $40.07B). The key difference: Alnylam Pharmaceuticals, Inc. and Prudential Financial Inc are close in size by market cap, and Prudential Financial Inc pays a 4.85% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PRU | |
|---|---|---|
Market Cap | $39.89B | $40.07B |
Sector | Health | Financials |
52-Week High | $491.22 | $118.72 |
52-Week Low | $278.09 | $92.00 |
Enterprise Value | $38.15B | $67.13B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PRU trades at $115.37, up 0.32% on the day, with a bullish technical signal and strong support at $113. The stock shows solid fundamentals with a P/E of 11.88 and net income margin of 5.5%, while recent earnings beats in Q1 2026 and dividend announcements highlight financial stability. News coverage emphasizes expansion in retirement products and international markets.
Outlook remains positive given valuation discounts and earnings momentum, though risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, but the stock's current technical strength and fundamental metrics support a steady growth trajectory for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
